Adaptive Biotechnologies (ADPT) COO sells 57K shares under 10b5-1 plan
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported a series of option exercises and share sales in March 2026. She exercised stock options to acquire a total of 44,166 shares of common stock at exercise prices of $6.55 and $7.27 per share, then sold 57,180 shares in open-market transactions.
The sales occurred in three equal blocks of 19,060 shares at weighted average prices of $13.18, $13.37 and $13.83 per share. All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following these trades, Rubinstein directly holds 481,906 shares of Adaptive Biotechnologies common stock.
Positive
- None.
Negative
- None.
Insights
Routine exercise-and-sell activity under a pre-planned Rule 10b5-1 trading plan.
President and COO Julie Rubinstein exercised options for 44,166 shares of Adaptive Biotechnologies common stock at strike prices of $6.55 and $7.27, then sold 57,180 shares in three open-market transactions at weighted average prices of $13.18, $13.37 and $13.83.
The filing notes these trades were made pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2025, indicating the timing was pre-scheduled rather than discretionary. After the transactions, Rubinstein still directly owns 481,906 shares, suggesting she retains a substantial equity position in the company.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | -- |
| Exercise | Common Stock | 14,722 | $7.27 | $107K |
| Sale | Common Stock | 19,060 | $13.83 | $264K |
| Exercise | Stock Option (right to buy) | 3,939 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 10,783 | $0.00 | -- |
| Exercise | Common Stock | 3,939 | $6.55 | $26K |
| Exercise | Common Stock | 10,783 | $7.27 | $78K |
| Sale | Common Stock | 19,060 | $13.37 | $255K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | -- |
| Exercise | Common Stock | 14,722 | $6.55 | $96K |
| Sale | Common Stock | 19,060 | $13.18 | $251K |
Footnotes (1)
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.23 to $13.59, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.51 to $14.07, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The option is fully vested and exercisable.
